• buy corel videostudio pro x2 online buy windows 7 pro 64 cheap dreamweaver 4 cheapest pinnacle studio 14 purchase omnifocus mac buy dreamweaver cs5.5 purchase microsoft word buy windows 7 student price canada buy windows server 2008 r2 web cheap server 2008 r2 dragon naturally speaking cheap purchase illustrator cs3 mac purchase revit structure office 2010 teacher discount buy autodesk autocad 2006
  • mindjet student discount guitar pro price cheapest ms office 2007 professional cheap anydvd hd buy adobe indesign australia buy anydvd canada discount windows 7 for students buy autocad 2000 lt buy autocad lt 2010 online price of pinnacle studio 12 cheap photoshop elements 9 microsoft office 2003 buy online clone dvd cheap best price windows 7 ultimate 32 bit cheapest 2007 publisher

    Positive data announced for Reolysin in head and neck cancers

    Sun, Dec 23, 2012

    Oral Cancer News

    Source: www.empr.com
    Author: staff

    Oncolytics Biotech announced positive top line data in its double-blinded randomized Phase 3 clinical study examining Reolysin in combination with carboplatin and paclitaxel in second-line patients with platinum-refractory, taxane-naïve head and neck cancers. Reolysin is a proprietary formulation of the human reovirus.

    A first analysis compared the relative percentages of patients in the test and control arms with tumors that had either stabilized or exhibited shrinkage. For the purposes of this endpoint, the definition of tumor stabilization was restricted to 0% growth only. Of the 105 total patients with evaluable metastatic tumors, 86% (n=50) of those in the test arm of the study exhibited tumor stabilization or shrinkage, compared with 67% of patients (n=55) in the control arm. This was statistically significant, with a p-value of 0.025.

    A second analysis examined the magnitude of tumor response on a per patient basis using a comparison of percentage tumor shrinkage at six weeks in each patient with evaluable metastatic tumors. This analysis showed that Reolysin in combination with carboplatin and paclitaxel was statistically significantly better than carboplatin and paclitaxel alone at stabilizing or shrinking metastatic tumors, yielding a p-value of 0.03

    Print Friendly
    Be Sociable, Share!
    , , , , , ,

    Leave a Reply

    You must be logged in to post a comment.